Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 5Phase 1 3Phase 1/2 2

Status

Active not recruiting 6Recruiting 4

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 4Genitourinary 2

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Disease Progression 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × capivasertib × Clear all
NCT04493853 2026-05-05

CAPItello-281

AstraZeneca

Phase 3 Active not recruiting
1,012 enrolled
Genitourinary

Prostatic Neoplasms

NCT04305496 2026-04-30

CAPItello-291

AstraZeneca

Phase 3 Active not recruiting
818 enrolled 19 charts 2 FDA
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT06764186 2026-04-08

CAPItana

AstraZeneca

Phase 3 Active not recruiting
101 enrolled
Breast

Breast Neoplasms

NCT06635447 2026-03-27

CAPItrue

AstraZeneca

Phase 3 Active not recruiting
258 enrolled
Breast

Breast Neoplasms, Disease Progression

NCT03997123 2025-12-22

CAPItello-290

AstraZeneca

Phase 3 Active not recruiting
923 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05348577 2025-01-27

CAPItello280

AstraZeneca

Phase 3 Active not recruiting
1,035 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡